The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Bojarskiy K.Yu.

Saint-Petersburg State Pediatric Medical University, St.-Petersburg, Russia, 194100;
Saint-Petersburg State Pediatric Medical University, St.-Petersburg, Russia, 194100

Libova T.A.

Saint-Petersburg State Pediatric Medical University, St.-Petersburg, Russia, 194100

The LH role in ovarian stimulation

Authors:

Bojarskiy K.Yu., Libova T.A.

More about the authors

Journal: Russian Journal of Human Reproduction. 2016;22(2): 17‑23

DOI: 10.17116/repro201622217-23

Read: 6434 times

Download PDF (RU)
Contact the author
Table of contents

THE LH ROLE IN OVARIAN STIMULATION
THE LH ROLE IN OVARIAN STIMULATION

To cite this article:

Bojarskiy KYu, Libova TA. The LH role in ovarian stimulation. Russian Journal of Human Reproduction. 2016;22(2):17‑23. (In Russ.)
https://doi.org/10.17116/repro201622217-23

 
Подписка 2026 Проблемы репродукции (Russian Journal of Human Reproduction)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

The introduction of recombinant LH is an important step in the development of ovarian stimulation. Initial data on the possibility of using these drugs only in patients with bad history (hypogonadotropic hypogonadism, poor response and older age of the patients) have been disproved by recent studies show the benefits of the combination of recombinant FSH and recombinant LH (in the ratio 2:1) over other drugs used during ovarian stimulation in IVF/ICSI cycles.

Keywords:

recombinant LH
ovarian stimulation

Authors:

Bojarskiy K.Yu.

Saint-Petersburg State Pediatric Medical University, St.-Petersburg, Russia, 194100;
Saint-Petersburg State Pediatric Medical University, St.-Petersburg, Russia, 194100

Libova T.A.

Saint-Petersburg State Pediatric Medical University, St.-Petersburg, Russia, 194100

Close metadata

References:

  1. Wide L, Eriksson K. Dynamic changes in glycosylation and glycan composition of serum FSH and LH during natural ovarian stimulation. Ups J Med Sci. 2013 Aug;118(3):153-164.  doi: 10.3109/03009734.2013.782081.
  2. Altmäe S, Hovatta O, Stavreus-Evers A, Salumets A.Genetic predictors of controlled ovarian hyperstimulation: where do we stand today? Hum Reprod Update. 2011 Nov-Dec;17(6):813-828.  doi: 10.1093/humupd/dmr034.
  3. Alviggi C, Pettersson K, Longobardi S, Andersen CY, Conforti A, De Rosa P, Clarizia R, Strina I, Mollo A, De Placido G, Humaidan P. A common polymorphic allele of the LH beta-subunit gene is associated with higher exogenous FSH consumption during controlled ovarian stimulation for assisted reproductive technology. Reprod Biol Endocrinol. 2013 Jun 1;11:51.  doi: 10.1186/1477-7827-11-51.
  4. O'Brien TJ, Kalmin MM, Harralson AF, Clark AM, Gindoff I, Simmens SJ, Frankfurter D, Gindoff P. Association between the luteinizing hormone/chorionic gonadotropin receptor (LHCGR) rs4073366 polymorphism and ovarian hyperstimulation syndrome during controlled ovarian hyperstimulation. Reprod Biol Endocrinol. 2013 Jul 25;11:71.  doi: 10.1186/1477-7827-11-71.
  5. Baerwald AR, Adams GP, Pierson RA. A new model for ovarian follicular development during the human menstrual cycle. Fertil Steril. 2003 Jul;80(1):116-122.  doi: http://dx.doi.org/10.1016/S0015-0282(03)00544-2.
  6. le Cotonnec JY, Porchet HC, Beltrami V, Munafo A. Clinical pharmacology of recombinant human luteinizing hormone: Part I. Pharmacokinetics after intravenous administration to healthy female volunteers and comparison with urinary human luteinizing hormone. Fertility and Sterility. 1998 Feb;69(2):189-194.  doi: http://dx.doi.org/10.1016/S0015-0282(97)00501-3.
  7. Boyarskiy KYu, Reznik V. A. Normosmic hypogonadotropic failure. Pediatrician. 2015;6:2:22-25. (In Russ.).
  8. Recombinant human luteinizinghormone (LH) to support recombinant human follicle-stimulatinghormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. The European Recombinant Human LH Study Group. J Clin Endocrinol Metab. 1998 May;83(5):1507-1514. doi: http://dx.doi.org/10.1210/jcem.83.5.4770.
  9. Carone D, Caropreso C, Vitti A, Chiappetta R. Efficacy of different gonadotropin combinations to support ovulation induction in WHO type I anovulation infertility: clinical evidences of human recombinant FSH/human recombinant LH in a 2:1 ratio and highly purified human menopausal gonadotropin stimulation protocols. J Endocrinol Invest. 2012 Dec 22;35(11):996-1002. Epub 2012 Oct 22.
  10. Shoham Z, Smith H, Yeko T, O'Brien F, Hemsey G, O'Dea L. Recombinant LH (lutropin alfa) for the treatment of hypogonadotrophic women with profound LH deficiency: a randomized, double-blind, placebo-controlled, proof-of-efficacy study. Clin Endocrinol (Oxf). 2008 Sep;69(3):471-478.  doi: 10.1111/j.1365-2265.2008.03299.x.
  11. Lisi F, Rinaldi L, Fishel S, Lisi R, Pepe GP, Picconeri MG, Campbell A. Use of recombinant LH in a group of unselected IVF patients. Reprod Biomed Online. 2002 Sep-Oct;5(2):104-108.  doi: http://dx.doi.org/10.1016/S1472-6483(10)61610-0.
  12. Humaidan P, Bungum M, Bungum L, Yding Andersen C. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reprod Biomed Online. 2004 Jun;8(6):635-643.  doi: http://dx.doi.org/10.1016/S1472-6483(10)61643-4.
  13. Marrs R, Meldrum D, Muasher S, Schoolcraft W, Werlin L, Kelly E. Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reprod Biomed Online. 2004 Feb;8(2):175-182.  doi: http://dx.doi.org/10.1016/S1472-6483(10)60513-5.
  14. Bühler K, Naether OG, Bilger W. A large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology. Reprod Biol Endocrinol. 2014 Jan 14;12:6.  doi: 10.1186/1477-7827-12-6.
  15. Bühler KF, Fischer R. Recombinant human LH supplementation versus supplementation with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol: a matched case-control study. Gynecol Endocrinol. 2012 May;28(5):345-350.  doi: 10.3109/09513590.2011.633128.
  16. Lehert P, Kolibianakis EM, Venetis CA, Schertz J, Saunders H, Arriagada P, Copt S, Tarlatzis B. Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and metaanalysis. Reprod Biol Endocrinol. 2014 Feb 20;12:17.  doi: 10.1186/1477-7827-12-17.
  17. Polyzos N, Sunkara SK. Sub-optimal responders following controlled ovarian stimulation: an overlooked group? Hum Reprod. 2015 Sep;30(9):2005-2008. doi: 10.1093/humrep/dev149.
  18. Simoni M, Nieschlag E, Gromoll J. Isoforms and single nucleotide polymorphisms of the FSH receptor gene: implications for human reproduction. Hum Reprod Update. 2002 Sep-Oct;8(5):413-421.  doi: 10.1093/humupd/8.5.413.
  19. Alviggi C, Clarizia R, Pettersson K, Mollo A, Humaidan P, Strina I, Coppola M, Ranieri A, D'Uva M, De Placido G. Suboptimal response to GnRHa long protocol is associated with a common LH polymorphism. Reprod Biomed Online. 2011 Feb;22(Suppl 1):S67-S72.  doi: http://dx.doi.org/10.1016/S1472-6483(11)60011-4.
  20. Bosch E, Ezcurra D. Individualised controlled ovarian stimulation (iCOS): maximising success rates for assisted reproductive technology patients. Reprod Biol Endocrinol. 2011 Jun 21;9:82.  doi: 10.1186/1477-7827-9-82.
  21. European Recombinant LH Study Group. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J Clin Endocrinol Metab. 2001 Jun;86(6):2607-2618. doi :http://dx.doi.org/10.1210/jc.86.6.2607.
  22. Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E, Fauser BCJM. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. The Journal of Clin Endocrinol Metab. 2003 Sep;88(9):4186-4192. doi: http://dx.doi.org/10.1210/jc.2002-021953.
  23. Fauser BCJM, Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab. 2003 Jul;14(5):236-242.  doi: http://dx.doi.org/10.1016/S1043-2760(03)00075-4.
  24. Kol S. Luteal support post GnRH agonist trigger: do not stop too soon. Hum Reprod. 2005 Nov;20(11):3257. doi: 10.1093/humrep/dei171.
  25. Nevo O, Eldar-Geva T, Kol S, Itskovitz-Eldor J. Lower levels of inhibin A and pro-alphaC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human chorionic gonadotropin. Fertil Steril. 2003;79:1123-1128.
  26. Papanikolaou EG, Verpoest W, Fatemi H, Tarlatzis B, Devroey P, Tournaye H. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. Fertil Steril. 2011 Mar 1;95(3):1174-1177. doi: http://dx.doi.org/10.1016/j.fertnstert.2010.09.023.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.